Results 261 to 270 of about 2,915,820 (347)
Frailty Exacerbates Disability in Progressive Multiple Sclerosis
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks +10 more
wiley +1 more source
Applying fairness in subnational carbon budget allocations. [PDF]
Lackner T +4 more
europepmc +1 more source
ABSTRACT Objective Plasma fibrinogen is essential in thrombosis and fibrinolysis, yet its dynamic changes pre‐ and post‐intravenous thrombolysis (IVT) for predicting brain injury severity and prognosis in acute ischemic stroke (AIS) patients remain unclear.
Wenhai Zhai +28 more
wiley +1 more source
Imperfect 10: Digital Advances and Market Impact in Fair Use Analysis [PDF]
Payne, Britton
core +1 more source
Making human derived data FAIR: feedback from NCI office of data sharing workshop. [PDF]
Ghosh M +9 more
europepmc +1 more source
Accounting harmonisation and the case of French use of the true and fair view
Peter Walton
openalex +1 more source
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source
FAIRness and data quality assessment of urban air quality monitoring datasets: Perspective on insights from F-UJI evaluation. [PDF]
Syed MSB, Kelly P, Stacey P, Berry D.
europepmc +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source

